Oncorus (NASDAQ:ONCR – Get Rating) and Perrigo (NYSE:PRGO – Get Rating) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their profitability, valuation, earnings, analyst recommendations, risk, institutional ownership and dividends.
Institutional and Insider Ownership
65.9% of Oncorus shares are owned by institutional investors. Comparatively, 96.4% of Perrigo shares are owned by institutional investors. 15.9% of Oncorus shares are owned by company insiders. Comparatively, 0.8% of Perrigo shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Get
Oncorus alerts:
Earnings & Valuation
This table compares Oncorus and Perrigo's top-line revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio |
| Oncorus | N/A | N/A | -$64.76 million | ($2.96) | -0.15 |
| Perrigo | $4.14 billion | 1.03 | -$68.90 million | ($0.63) | -50.49 |
Oncorus has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Oncorus, indicating that it is currently the more affordable of the two stocks.
Volatility & Risk
Oncorus has a beta of 2.24, indicating that its share price is 124% more volatile than the S&P 500. Comparatively, Perrigo has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500.
Analyst Ratings
This is a summary of current recommendations and price targets for Oncorus and Perrigo, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score |
| Oncorus | 0 | 2 | 1 | 0 | 2.33 |
| Perrigo | 0 | 0 | 3 | 0 | 3.00 |
Oncorus currently has a consensus target price of $5.25, indicating a potential upside of 1,090.48%. Perrigo has a consensus target price of $47.33, indicating a potential upside of 48.80%. Given Oncorus' higher probable upside, research analysts clearly believe Oncorus is more favorable than Perrigo.
Profitability
This table compares Oncorus and Perrigo's net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets |
| Oncorus | N/A | -72.31% | -42.11% |
| Perrigo | -1.93% | 5.31% | 2.47% |
Summary
Perrigo beats Oncorus on 7 of the 13 factors compared between the two stocks.
About Oncorus
(Get Rating)
Oncorus, Inc., a clinical-stage biopharmaceutical company, focuses on developing viral immunotherapies for cancer patients. The company's lead product candidate is ONCR-177, an intratumorally administered viral immunotherapy based on its oncolytic herpes simplex virus type 1 platform, which is in Phase I clinical trials for treating various cancers. It is also developing ONCR-GBM, a preclinical stage oHSV program for treating brain cancer through intratumoral injection; and synthetic viral immunotherapies based on Coxsackievirus A21 and Seneca Valley Virus. The company has a clinical trial collaboration and supply agreement with MSD International GmbH to evaluate the safety and tolerability of ONCR-177 combined with Merck's cancer immunotherapy KEYTRUDA in its Phase 1 clinical trial in patients with solid tumors. Oncorus, Inc. was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
About Perrigo
(Get Rating)
Perrigo Company plc provides over-the-counter (OTC) health and wellness solutions that enhance individual well-being by empowering consumers to prevent or treat conditions that can be self-managed. The company operates through two segments, Consumer Self-Care Americas and Consumer Self-Care International. The Consumer Self-Care Americas segment focuses primarily on the development, manufacture, marketing, and sale of store brand, self-care products in categories, including upper respiratory, pain and sleep-aids, digestive health, nutrition, vitamins, minerals and supplements, healthy lifestyle, skincare and personal hygiene, and oral self-care in the United States, Mexico, Canada, and South America. The segment offers its products under the Prevacid 24HR, Good Sense, Zephrex D, ScarAway, Plackers, Rembrandt, Steripod, Firefly, REACH, Dr. Fresh, and Burt's Bees brand names. The Consumer Self-Care International segment develops, manufactures, markets, and distributes consumer self-care brands through a network of pharmacies, wholesalers, drug and grocery store retailers, and para-pharmacies in approximately 23 countries, primarily in Europe. The company also offers contract manufacturing services. Perrigo Company plc was founded in 1887 and is headquartered in Dublin, Ireland.
Receive News & Ratings for Oncorus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oncorus and related companies with MarketBeat.com's FREE daily email newsletter.
